Projects per year
Objective: The objective of this study is to establish the efficacy of preoperative VRT in reducing postoperative complications in diabetic patients undergoing CABG surgery. Time to “fit for discharge”, incidence of post-operative renal failure, cardiac injury, inflammation, and other health outcomes will be investigated.
Methods: In this open parallel group randomised controlled trial 170 diabetic patients undergoing elective or urgent CABG surgery will receive 1 ml/kg/hr of Hartmann’s solution for 12 consecutive hours prior to surgery versus routine care. The primary outcome will be time until participants are ‘fit for discharge’ defined as presence of normal temperature, pulse and respiration, normal oxygen saturation on air, normal bowel function and physically mobility. Secondary outcomes will include incidence of renal failure, markers of renal function, inflammation, and cardiac damage, operative morbidity, intensive care stay, patient-assessed outcome including the Coronary Revascularisation Outcome Questionnaire (CROQ), and use of hospital resources.
Results: Recruitment started in July 2010. Enrolment for the study was completed in July 2014. Data analysis commenced in December 2016. Study results will be submitted for publication in the spring of 2017.
Conclusions: VRT is a relatively easy treatment to administer in patients at risk of renal failure undergoing surgical procedures. This experimental protocol will increase scientific and clinical knowledge of VRT in diabetic patients undergoing elective or urgent CABG surgery. Findings supporting the efficacy of this intervention could be easily implemented in the healthcare system.
Trial registration: ISRCTN02159606
- BTC (Bristol Trials Centre)
- Centre for Surgical Research
- Coronary artery bypass surgery
- diabetes mellitus
- renal failure
- volume replacement therapy
- clinical trials